公司简介
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...
关联新闻
- Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.
2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert sai...
- Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
Revolution Medicines attracted takeover interest but decided to go it alone. This week's FDA approval of its pancreatic cancer pill is the payoff.
- Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,' has been granted approval in patients with pancreatic adenocarcinoma.
- The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis
The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years.